All In Biotech

Free tool

FAERS Monitor: Unloxcyt

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761297 or its brand name (Unloxcyt, Cosibelimab-Ipdl). Reports on generic versions are filed under their own applications.

Reports

7

Serious

1

14% of reports

Hospitalization

0

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • alopecia1
  • death1
  • fatigue1
  • illness1
  • liver disorder1
  • product storage error1
  • product storage issue1
  • pruritus1
  • swelling face1
  • therapy cessation1

Reports by year received

View as table
YearReports
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,152 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product storage issue1793.4129.2197
liver disorder167.811.016
therapy cessation158.59.514
swelling face146.17.511
product storage error134.35.68
illness129.24.86
alopecia115.32.53
pruritus17.81.31
fatigue13.90.60
death13.50.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.